Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients

The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.

Inclusion Criteria:

• Male and female patients of any race between 18 to 70 years old (inclusive)
• Patients who gave written informed consent to participate in the study

Exclusion Criteria:

• Recipients of multi-organ transplantation
• Recipients of a primary cadaveric or primary non-human leucocyte antigen (HLA) identical living donor kidney transplantation.
• Graft cold ischemia time greater than 40 hours.

Other protocol-defined inclusion/exclusion criteria may apply.